Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shiwei Wenshen Pill is a Traditional Chinese Medicine (TCM) hospital preparation developed by The First Affiliated Hospital of Henan University of Chinese Medicine. It is specifically formulated to treat erectile dysfunction (ED) characterized by the TCM patterns of kidney deficiency and liver stagnation. The "Shiwei" (ten ingredients) designation indicates a polyherbal composition designed to "warm the kidney" (Wenshen) and regulate liver qi to restore sexual function. In clinical research, it is frequently evaluated as an adjunct therapy to phosphodiesterase-5 (PDE5) inhibitors, such as low-dose tadalafil, to enhance clinical efficacy, improve erectile function scores, and potentially reduce the side effects associated with standard pharmacological treatments for impotence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shiwei Wenshen Pill.